TB-840 / Therasid Biosci - LARVOL DELTA

Safety, Pharmacokinetics, and Food Effect of the RORα Agonist TB-840, a Novel Candidate for Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Randomized First-in-Human Study in Healthy Volunteers. (PubMed, Life (Basel)) - P1 | "These results support the continued development of TB-840 as a potential treatment for MASH. Further studies are warranted to evaluate its efficacy and safety in the target patient population (ClinicalTrials.gov identifier: NCT05045534)."

First-in-human • Journal • P1 data • PK/PD data • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of TB-840 in Healthy Subjects (clinicaltrials.gov) - P1 | N=96 | Completed | Sponsor: Therasid Bioscience | Recruiting ➔ Completed

Trial completion • Hepatology • Non-alcoholic Steatohepatitis

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of TB-840 in Healthy Subjects (clinicaltrials.gov) - P1; N=88; Recruiting; Sponsor: Therasid Bioscience; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Hepatology • Non-alcoholic Steatohepatitis

The Purpose of This Study is to Determine Whether TB-840 is Effective in the Treatment of Subjects With Non-alcoholic Steatohepatitis (NASH) (clinicaltrials.gov) - P1; N=88; Not yet recruiting; Sponsor: Therasid Bioscience

Clinical • New P1 trial • Hepatology • Non-alcoholic Steatohepatitis